Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07045298 · ClinicalTrials.gov registry record · NA
CGM Use in Heart Failure
A NA study, sponsored by Emory University.
- Not yet
- Registry status
- NA
- Development phase
- 140
- Enrollment target
NCT07045298: Clinical Trial NA study, sponsored by Emory University.
NCT07045298 is a NA study that has not yet begun recruiting, run by Emory University. The registered enrollment target is 140 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07045298, a NA study, has not yet begun recruiting, sponsored by Emory University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 140 participants
- Enrollment target
Study Summary
Heart failure (HF) is a major cause of hospital admissions in the US, with over 6 million hospital days annually. More than 40% of hospitalized patients with HF have diabetes mellitus (DM), which increases the risk of recurrent hospitalizations for HF with reduced and preserved ejection fraction by more than two-fold. Current methods for assessing glycemic control do not consider fluctuations in blood glucose levels, known as glycemic variability. High glycemic variability is a poor prognostic marker for HF re-hospitalizations. Given the significant prevalence and impact of DM in individuals with HF, it is crucial to examine whether improving glycemic control and avoiding hypoglycemia could lead to a decrease in HF readmissions. Real-time continuous glucose monitoring (rt-CGM), which provides glucose measurements as frequently as every 5 minutes, has improved glycemic control in insulin-treated adults with DM compared to the standard of care, capillary point-of-care blood glucose testing (POC). Researchers will monitor participants during their hospital stay and 3 months after discharge.
Primary Outcome
Glucose levels measured by RT-CGM compared to traditional glucose monitoring testing (POCT-BG)
Interventions
- DEVICE Libre 2 rt-CGM
- DIAGNOSTIC_TEST POC BG + Blinded CGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-04 |
| Phase | NA |
What is known before NCT07045298 opens enrollment
NCT07045298 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Libre 2 rt-CGM is the first listed.
NCT07045298 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07045298 about?
NCT07045298 is a clinical study titled "CGM Use in Heart Failure". Heart failure (HF) is a major cause of hospital admissions in the US, with over 6 million hospital days annually. More than 40% of hospitalized patients with HF have diabetes mellitus (DM), which increases the risk of recurrent hospitalizations for HF with reduced and preserved ejection fraction by...
What is the current status of trial NCT07045298?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 140 participants. The study started on 2026-04. Estimated completion is 2027-04.
What interventions are being tested in trial NCT07045298?
The interventions under investigation include: Libre 2 rt-CGM (DEVICE), POC BG + Blinded CGM (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07045298?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07045298's enrollment target sits among peer trials
140 713th of 2000 higher than 1,281 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia